未名医药: 关于控股子公司暂停生产、销售的进展及风险提示公告

Core Viewpoint - Tianjin Weiming Bio-Pharmaceutical Co., Ltd. has been subjected to production and sales suspension measures by the Tianjin Municipal Drug Administration due to non-compliance with Good Manufacturing Practice (GMP) standards, significantly impacting the company's operations and financial performance [1][2][3] Group 1: Suspension Overview - The suspension was initiated after a GMP compliance inspection revealed that Tianjin Weiming's production practices did not meet regulatory requirements, leading to a halt in production and sales to mitigate quality and safety risks [1][2] - In 2024, Tianjin Weiming generated revenue of RMB 216.57 million and incurred a net loss of RMB 14.00 million, accounting for 60.09% of the company's total revenue and 9.8% of the consolidated net profit [1][2] Group 2: Impact on the Company - The suspension of Tianjin Weiming's operations is expected to adversely affect the company's sales and cash flow during the remediation period, which is anticipated to last no longer than three months [2][3] - The company has established a special rectification team and is actively cooperating with regulatory authorities to address the identified deficiencies [2]